Among all SARS-CoV-2 RT-PCR-positive samples identified in our laboratory, all those with a Ct value ≤ 32 are subsequently screened for the 501Y and 484K mutation by specific RT-PCR assays.
Specimens analyzed in our laboratory come from the community (majority), from hospital workers (systematic screening in case of any symptoms and cluster investigations), from asymptomatic travelers, and from hospitalized patients.
Follow-up of previous updates in Geneva

501Y and 484K mutation screening by RT-PCR among SARS-CoV-2 positive samples collected in GE and sent to our laboratory for primary diagnosis

Almost all new positive cases are now due to a variant carrying the 501Y mutation. Only few samples carrying the 484K mutations (P.1 Brazil and B.1.351 South-Africa) have been identified over the past 7 days. Some samples, displaying the 484K without the 501Y mutation has been detected, and are currently being sequenced. This combination is rarely observed in Geneva.
Most recent whole genome sequencing results performed on SARS-CoV-2 positive samples collected in GE and sent to our laboratory

WGS is carried out in close collaboration with the Health 2030 Genome Center in Geneva and is based on a daily random sampling of SARS-CoV-2 positive specimens by RT-PCR with as only selection criterion a Ct value ≤ 32. This graph displays the sequences with 95% of positions covered ≥ 15x and submitted to GISAID (293 sequences obtained from samples collected from February 16 to February 25, 2021).

The predominant variant is still B.1.1.7, as confirmed by whole genome sequencing. Few B.1.351 are also circulating at a low level. P.1 sequences are only rarely retrieved. No other variants were identified in the Geneva area from February 16 to February 25, 2021.

Conclusions

The B.1.1.7 variant is representing almost all new SARS-CoV-2 contaminations in the Geneva area. Only few samples carrying the 484K mutation (Brazilian P.1 or South Africa B.1.351) are detected each week.